Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope dashed: drug trial for Post-COVID racing heart stopped early

NCT ID NCT06524739

Disease control Sponsor: CSL Behring Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called IgPro20 (HIZENTRA) to see if it could help people with post-COVID POTS, a condition that causes a rapid heart rate and dizziness when standing. The trial was stopped early after enrolling only 16 adults. The goal was to see if the drug could reduce symptoms and improve daily life, but results are limited due to early termination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

16 people

The number who actually took part.

Started

Aug 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provide written informed consent and be willing and, in the opinion of the investigator, able to adhere to all protocol requirements. 2. Males and females aged ≥ 18 at the time of providing written informed consent. 3. Diagnosis of post-COVID POTS, defined by both a preceding COVID-19 infection based on confirmed historical documentation and onset of POTS symptoms developing within 4 months after COVID-19 infection as defined per consensus criteria. 4. COMPASS-31 score of at least 40 at the Screening visit. 5. Positive confirmatory standardized standing test (ie, HR increase of ≥ 30 bpm \[≥ 40 bpm for participants aged 18 to 19 years\] within 10 minutes in the absence of orthostatic hypotension) at the Screening visit. Exclusion Criteria: 1. Treatment with Immunoglobulin G (IgG) or plasmapheresis within 12 weeks before Screening 2. Symptoms and / or diagnosis of or receiving treatment for POTS before COVID-19 infection 3. Prior diagnosis of or receiving current treatment at Screening for the following conditions (unless onset was related to the inciting POTS-associated COVID-19 infection): certain neurologic, autoimmune, endocrine, cardiac, or other disorders, and pre-existing psychiatric disorders 4. Presence of active infections, including human immunodeficiency virus infection, hepatitis B, hepatitis C, active SARS-CoV-2 infection, or any uncontrolled systemic infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-COVID postural orthostatic tachycardia syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder postural orthostatic tachycardia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-COVID postural orthostatic tachycardia syndrome

Contacts and locations

Locations

  • Arkansas Cardiology Clinic - Little Rock

    Little Rock, Arkansas, 72205, United States

  • Bateman Horne Center

    Salt Lake City, Utah, 84102, United States

  • Bernstein Clinical Research Center

    Cincinnati, Ohio, 45236, United States

  • Center for Complex Neurology, EDS & POTS

    Phoenix, Arizona, 85006, United States

  • Ciussse-Chus

    Sherbrooke, J1H 5N4, Canada

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Dysautonomia Clinic

    Buffalo, New York, 14221, United States

  • Hightower Clinical

    Oklahoma City, Oklahoma, 73134, United States

  • Hope Research Network

    Miami, Florida, 33166, United States

  • Johns Hopkins Bayview Medical Center PMR

    Baltimore, Maryland, 21224, United States

  • LSU Health Sciences Center

    New Orleans, Louisiana, 70112, United States

  • Libin Cardiovascular Institute University of Calgary

    Calgary, T2N 4Z6, Canada

  • Mass General Brigham (Massachusetts General Hospital)

    Belmont, Massachusetts, 02478, United States

  • Mayo Clinic Arizona

    Scottsdale, Arizona, 85259, United States

  • McGill University Health Centre

    Québec, H4A 3J1, Canada

  • Metrodora Institute

    West Valley City, Utah, 84119, United States

  • NYU Langone Health South Shore Neurologic Associates

    Patchogue, New York, 11772, United States

  • National Jewish Health

    Denver, Colorado, 80206, United States

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania, 19104, United States

  • Profound Research LLC at Millennium Affiliated Physicians

    Farmington Hills, Michigan, 48334, United States

  • Prolato Clinical Research Center

    Houston, Texas, 77054, United States

  • Sunbeam Clinical Research

    McKinney, Texas, 75069, United States

  • UC San Diego Health

    La Jolla, California, 92037, United States

  • UT Austin Dell Medical School

    Austin, Texas, 78712, United States

  • University Hospital Cleveland Medical Center

    Cleveland, Ohio, 44195, United States

  • University of Alabama Hospital at Birmingham

    Birmingham, Alabama, 35294-1152, United States

  • University of Alberta Hospital

    Edmonton, T6G 2B7, Canada

  • University of Texas Health Science Center

    San Antonio, Texas, 78229, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of california Irvine

    Orange, California, 92868, United States

  • VCU Health

    Richmond, Virginia, 23219, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Velocity Clinical Research - Hampton

    Hampton, Virginia, 23666, United States

  • Velocity Clinical Research - Lincoln

    Lincoln, Nebraska, 68510, United States

  • Velocity Clinical Research - Union

    Union, South Carolina, 29379, United States

  • Velocity Clinical Research, Metairie

    New Orleans, Louisiana, 70119, United States

  • Velocity Clinical Research, Savannah

    Savannah, Georgia, 31406, United States

  • Well Pharma Medical Research, Corp

    Miami, Florida, 33173, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.